A few changes in the world of GLP-1 agonists are making the drugs more accessible to people, even if their health care plans don't cover them
Future studies should consider increasing the number of participants to enhance the statistical power and generalizability of the findings
Other pharmacotherapies, such as naltrexone/bupropion, have not been associated with increased cancer risk
These drugs work by mimicking the action of the naturally occurring GLP-1 hormone, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety
The FDA prescribing information for Wegovy states that semaglutide should be discontinued at least 2 months before a planned pregnancy [3]
She cautioned that the GLP-1 drugs don't work the same way for all users and that they have risks that must be weighed against potential benefits